Myriad Settles BRCA Testing Patent Fray with Pathway Genomics, Invitae

Following Myriad's June 2014 lawsuit for infringement of its patent claims underlying BRCA1 and BRCA2 genetic testing, Myriad Genetics and other patent owners have settled their BRCA testing patent lawsuit with Pathway Genomics and Invitae.